{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-023083","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2024-03-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.351960+00:00","generated_at":"2026-06-04T17:06:24.680640+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"medium","headline":"NeuroOne shareholders elect director, ratify auditor, approve exec compensation vote every three years","bullets":["Paul Buckman elected Class I director: 5,804,908 for, 1,363,109 withheld, 8,614,407 broker non-votes.","Ratification of Baker Tilly as independent auditor: 15,736,069 for, 36,991 against, 9,364 abstain.","Advisory approval of named executive officer compensation: 6,586,582 for, 330,506 against, 250,929 abstain.","Advisory vote on frequency of exec compensation votes: every three years selected (3,723,836 votes); board to implement that cycle.","60.89% of shares represented at meeting (15,782,424 of ~25.9M shares outstanding)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-023083","json":"https://secwatch.observer/filing/0001213900-24-023083.json","markdown":"https://secwatch.observer/filing/0001213900-24-023083.md","text":"https://secwatch.observer/filing/0001213900-24-023083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/0001213900-24-023083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/ea0201844-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T17:06:24.680640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c7c51f9a3325f1de35eed1075ee2c80ffb8bc36","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Election of Class I director Paul Buckman at the 2024-03-14 meeting.","evidence_excerpt":"Proposal 1—Election of Directors Class I Nominee Votes For Votes Withheld Broker Non-Votes Paul Buckman 5,804,908 1,363,109 8,614,407","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/0001213900-24-023083-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-14"}],"fact_type":"shareholder_vote"},{"claim_id":"6b51ee82f334d56e2c109a9cbe39e2989ab70f8d","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Ratification of appointment of Baker Tilly U.S., LLP as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-03-14 meeting.","evidence_excerpt":"Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 15,736,069 36,991 9,364","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/0001213900-24-023083-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-14"}],"fact_type":"shareholder_vote"},{"claim_id":"772bd68bb47ec67fa6df8b13a31531924a0e8673","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Advisory approval of frequency of future advisory votes on executive compensation: every three years (the frequency receiving the majority of votes cast) at the 2024-03-14 meeting.","evidence_excerpt":"Proposal 4—Advisory Approval of the Frequency of an Advisory Vote on Named Executive Officers Compensation One Year Two Years Three Years Votes Abstain 3,060,695 144,245 3,723,836 239,241 For Proposal 4, “every three years” received the affirmative vote of the holders of a majority of the voting power of shares present","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/0001213900-24-023083-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-14"}],"fact_type":"shareholder_vote"},{"claim_id":"e074d67e22be5d92e97a9ed598a0bd71e3e8dd5a","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp shareholders approved Approval of the Company's named executive officers' compensation in an advisory vote at the 2024-03-14 meeting.","evidence_excerpt":"Proposal 3—Approval of the Company’s Named Executive Officers’ Compensation in an Advisory Vote Votes For Votes Against Votes Abstain 6,586,582 330,506 250,929","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390024023083/0001213900-24-023083-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-03-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}